Background {#Sec1}
==========

The majority of germ cell tumors are mature cystic teratomas, which account for approximately 15--20 % of all ovarian tumors \[[@CR1]\]. Of these, 15 % contain thyroid tissue \[[@CR2], [@CR3]\]. Struma ovarii is diagnosed when thyroid tissue comprises more than 50 % of the teratoma \[[@CR4], [@CR5]\]. Struma ovarii accounts for only 2 % of all mature teratomas, and less than 5 % of struma ovarii present malignant transformation \[[@CR4], [@CR6], [@CR7]\]. Owing to malignant struma ovarii (MSO) rarity, there has been some controversy about the diagnosis and treatment, and prognosis is difficult to evaluate.

We report an unusual case of papillary thyroid cancer in MSO, with metastasis to the omentum. Here, we presented a review of literature including the clinicopathologic features, differential diagnosis, and management.

Case presentation {#Sec2}
=================

A 40-year-old female presented with an incidental finding of a pelvic mass during her obstetric examination before 6 years. A palpable mass was noted in the left-sided pelvis on physical examination. The patient did not have special symptoms and ascites. Abdominal ultrasonography (Voluson S8, General Electric Company, USA) revealed a 3.0 × 3.1 cm mixed echogenicity mass in the left adnexa, suggestive of an ovarian teratoma. The data obtained by routine blood, urine, and thyroid function tests, as well as tumor markers, were in the normal range. The patient had no history of thyroid dysfunction and no family history of ovarian or endocrine tumors. The patient had no relevant past interventions. Malignancy could not be excluded.

The patient underwent laparoscopic ovarian cyst divesting surgery. At exploration, the uterus, right ovary, and fallopian tube were normal. The left ovary was enlarged, and a benign-looking white and smooth ovarian cystic mass was noted. Upon sectioning, the ovarian mass was partially cystic and grossly resembled papillary tumor. The peritoneal washing was negative on cytological examination. An intra-operative frozen and permanent paraffin section was proved to be a malignant struma ovarii with multiple foci of papillary thyroid carcinoma (Fig. [1a](#Fig1){ref-type="fig"}). In the papillary thyroid carcinoma focus, papillary thyroid tissue with increased mitotic activity and ground glass nuclei, intra-nuclear inclusions were detected. Also, a few psammoma bodies were identified. The tumor was restricted within the capsule, and vascular invasion was not identified. Immunohistochemically, tumor cells were strongly positive for thyroglobulin (Tg), thyroid transcription factor-1 (TTF-1), galetin-3, cytokeratin-19 (CK19), and human bone marrow endothelial cell-1 (HBME-1) (Fig. [2](#Fig2){ref-type="fig"}). Based on all these findings, the diagnosis was papillary thyroid cancer arising within malignant struma ovarii. Thus, 1 week later, the patient underwent a cytoreductive surgery (hysterectomy, bilateral salpingectomy and oophorectomy, omentectomy, appendectomy, and pelvic lymphadenectomy). The pathologic examination showed no metastatic neoplasm was found, except on the omentum material (Fig. [1b](#Fig1){ref-type="fig"}). After surgery, the patient with stage FIGO IIIc received 6 cycles systemic chemotherapy of paclitaxel (175 mg/m^2^; over 3 h intravenous infusion) plus carboplatin (area under the curve \[AUC\] = 5; over 1 h intravenous infusion), given on day 1 of a 21-day cycle. Patient subsequently had a thyroid scan that was normal with normal thyroid function.Fig. 1H&E staining of malignant struma ovarii tissues. H&E staining (**a**) showed fibrous cores of tissue lined by neoplastic cells which contain large overlapping "ground-glass" nuclei characteristic of thyroid papillary carcinoma. **b** Metastasis to omentum is shown (H&E, original magnifications ×400) Fig. 2Immunohistochemical (CK19, galetin-3, HBME-1) staining of malignant struma ovarii tissues. **a** CK19 was diffuse and strong cytoplasmic staining in MSO. **b** MSO showing strong cytoplasmic staining of galectin-3. **c** MSO with beautiful complex papillae exhibits a HBME-1 membrane staining pattern (immunohistochemistry, original magnifications ×400)

Discussion {#Sec3}
----------

Struma ovarii is a teratoma in which thyroid tissue is present exclusively or forms a grossly recognizable component of a more complex teratoma \[[@CR8]\]. The rate of malignant transformation in struma ovarii is extremely low. The mean age at diagnosis of MSO was 43 years old \[[@CR6], [@CR9]\]. Most cases of MSO are subclinical. Clinical hyperthyroidism manifestations are seen in 5--8 % of the cases \[[@CR10]\]. Moreover, insufficient concordance between morphologic features and clinical outcome in MSO is striking, making the behavior of these tumors particularly unpredictable \[[@CR11]\]. It is reported that *BRAF V600E* gene mutations, a common pathogenesis for all papillary thyroid cancers, regardless of body location, were present in two thirds of MSO with papillary features \[[@CR12]\].

The predominant sites of metastasis were adjacent pelvic structures, including the contralateral ovary; hematologic dissemination includes metastases of the lung, bone, liver, and brain, but metastasis is rare in patients with MSO. In this case, the patient had omentum metastasis. The reason is that the tumor can spread via regional lymphatics to pelvic and paraaortic lymph nodes and can directly infiltrate the omentum \[[@CR11], [@CR13]\].

Since it is a rare type of germ cell tumor encountered, there are no uniform diagnostic criteria for MSO. MSO is most often diagnosed postoperatively. The histopathological diagnosis adheres to the same criteria used for thyroid carcinoma: "ground glass" overlapping nuclei and nuclear grooves, or mitotic activity and vascular invasion \[[@CR4]\]. Eighty-five percent of papillary carcinomas with the characteristics are "ground glass" nuclei. All pathologic patterns of thyroid gland malignancy may be found in struma ovarii, and papillary carcinoma is the most common \[[@CR14]--[@CR16]\]. Immunohistochemical staining with Tg, HBME-1, and galectin-3, often positive in papillary thyroid carcinoma, can also help confirm the diagnosis and are necessary for differential diagnosis from carcinoid and granulosa cell tumors \[[@CR17], [@CR18]\].

The absence of a primary lesion in the thyroid is necessary to exclude metastatic thyroid carcinoma to the ovary \[[@CR4], [@CR11]\]. The differential diagnosis from thyroid-type cancers from the thyroid and ovary depends on immunohistochemical stains for CK19 and TTF-1, supporting the independent existence of two cancers. Besides family history and a physical examination followed by an ultrasound of the thyroid gland, it is reported that unique characteristics on ovarian magnetic resonance imaging (MRI) might help to differentiate the two diseases.

The optimal treatment regimen for MSO is currently debated due to the difficulty to distinguish between benign and malign struma ovarii. Most authors advocate for an aggressive treatment based on TAH/BSO, lymph-node dissection and omentectomy, followed by adjuvant therapy, including external radiotheraphy, chemotheraphy, and thyroid suppression, regardless of the presence of distant metastases at time of diagnosis.

MSO might be over-treated, and this might impact long term the quality of life and fertility of affected women. Thus, conservative treatment such as unilateral oophorectomy should be the choice for patients who wish to fertility preservation, if pelvic imaging and surgical exploration do not reveal extra-ovarian disease \[[@CR9], [@CR19]\].

In addition, on the basis of the similarities between MSO and thyroid carcinoma, near-total thyroidectomy followed by radioactive iodine (I^131^) should be first-line therapy for patient with a higher risk of recurrence or with palindromia \[[@CR12]\]. Treatment with thyroxine was not documented consistently enough to determine its impact on recurrence rates.

Patients with MSO had an excellent disease-specific survival rate, regardless of the management strategy employed. In 2015, Adam et al. published a study that included 68 patients with MSO \[[@CR9]\]. The data indicated that overall survival rates for all patients were 94.3 % at 10 years and 84.9 % at 20 years, which was in agreement with the finding by Robboy et al. published in 2009 \[[@CR20]\]. After TAH/BSO and chemotherapy, our patient is currently disease-free for the past 1 year. But long-term follow-up with thyroglobulin levels is necessary due to reports of increasing recurrence rates.

Conclusions {#Sec4}
===========

Based on the rarity of these tumors and their lack of firm prognostic factors, treatment decisions should be made individually, based on pathologic and clinical parameters.

Consent {#Sec5}
-------

Written informed consent was obtained from the owner of the patient for the publication of this case presentation and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
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